Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed metastatic renal cell carcinoma (RCC) with predominantly clear cell histology * Measurable disease * No history of tumor-related hemorrhage * No history of CNS or brain metastases PATIENT CHARACTERISTICS: * Karnofsky performance status ≥ 80% * Absolute neutrophil count ≥ 1,000/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9 g/dL (transfusion or recombinant erythropoietin growth factors allowed) * AST ≤ 2 times upper limit of normal (ULN) (5 times ULN if due to liver metastases) * Serum total bilirubin ≤ 2 times ULN (except for patients with Gilbert's disease) * Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min * FEV\_1 ≥ 2.0 L or ≥ 75% of predicted * Pulmonary function testing required for patients over age 50 or with significant pulmonary or smoking history * No history of cerebrovascular accident or transient ischemic attacks * No evidence of any of the following cardiac conditions\*: * Congestive heart failure * Symptoms of coronary artery disease * Myocardial infarction \< 6 months prior to study entry * Serious cardiac arrhythmias * Unstable angina NOTE: \*Patients \> 40 years old or who have had a previous myocardial infarction \> 6 months prior to study entry are required to have a negative or low probability cardiac stress test for cardiac ischemia * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No other malignancy within the past 5 years except nonmelanoma skin cancer or noninvasive cancer, such as cervical carcinoma in situ, superficial bladder cancer without local recurrence, or breast cancer in situ * Patients with a history of another invasive malignancy must be in complete remission for ≥ 5 years * No positive serology for HIV, hepatitis B, or hepatitis C * No significant co-morbid illness, such as uncontrolled diabetes or active infection, that would preclude study treatment * No history of inflammatory bowel disease or other serious autoimmune disease * Thyroiditis or rheumatoid arthritis allowed * No uncontrolled hypertension (i.e., blood pressure \> 150/100 mm Hg) * Proteinuria ≤ 3+ by dipstick OR proteinuria \< 2 gm by 24-hour urine collection * Urine protein:creatinine ration \< 1.0 * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study entry * No significant traumatic injury within the past 28 days * No serious, nonhealing wound, ulcer, or bone fracture * No active bleeding * No history of other serious hemorrhage, bleeding diathesis, or underlying coagulopathy * No history of deep venous thrombosis, clinically significant peripheral vascular disease, or other thrombotic event PRIOR CONCURRENT THERAPY: * No organ allografts * At least 4 weeks since prior radiotherapy or surgery and recovered * No prior systemic therapy for metastatic RCC * No prior bevacizumab or interleukin-2 * At least 2 weeks since prior steroids * No major surgery or open biopsy within the past 28 days * No minor surgical procedures, fine needle aspirations, or core biopsies within the past 7 days, except central venous catheter placement * No concurrent major surgery * No concurrent corticosteroids or other immunosuppressants